01—Abstract
Summary
Summary of the 10-K filed February 13, 2019. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported total revenue of $2,266,096 thousanda ($2.27 billion) for fiscal 2018, up from $1,857,601 thousand in 2017, a 22.0% increase that the filing attributes primarily to growth in the DSA and Manufacturing segments and the acquisitions of MPI Research, KWS BioTest and Brains On-Line.
Operating income rose to $331,383 thousandb from $288,282 thousand, and net income attributable to common shareholders increased to $226,373 thousand from $123,355 thousand. Diluted earnings per share from continuing operations were $4.59, compared with $2.54 in 2017, helped by a lower effective tax rate of 19.3% versus 57.7%, which reflected the net effects of U.S. Tax Reform. Net cash provided by operating activities was $441,140 thousand, up from $318,074 thousand.
The company's debt rose to $1,654,988 thousandc in total debt at year-end 2018, driven by the $2.3B Credit Facility and a $500.0 million 5.5% Senior Notes offering used largely to fund the $829.7 million cash purchase of MPI Research. Cash flows from investing activities totaled $955,003 thousand in outflows, including $824,868 thousand for business acquisitions and $140,054 thousand in capital expenditures. The company did not repurchase shares under its program during 2018, leaving $129.1 million authorized.
Management describes demand for its safety assessment and biologics services as robust, while research model demand outside China declined. Subsequent to year-end, on February 13, 2019, Charles River signed a binding offer to acquire Citoxlab for EUR 448 million in cash (approximately $510 milliond), expected to close in the second quarter of 2019 and to be financed through its revolving credit facility and cash. The filing also notes a planned termination of the U.S. pension plan, with the company expecting to complete the process over the next two years.
02—Key points
Key Highlights
- Total revenue of $2,266,096 thousand in fiscal 2018, up 22.0% from $1,857,601 thousand in 2017.
- DSA segment revenue of $1,316,854 thousand, up 34.4%, representing 58.1% of total 2018 revenue, with $209.5 million contributed by MPI Research since its April 2018 acquisition.
- Operating income of $331,383 thousand (14.6% operating margin) versus $288,282 thousand (15.5%) in 2017.
- Diluted EPS from continuing operations of $4.59 versus $2.54 in 2017; effective tax rate fell to 19.3% from 57.7%.
- Total debt of $1,654,988 thousand at December 29, 2018, up from $1,120,539 thousand, including a $500.0 million 5.5% Senior Notes due 2026.
- Pending acquisition of Citoxlab for EUR 448 million (approximately $510 million), announced February 13, 2019 and expected to close in the second quarter of 2019.
- Net cash provided by operating activities of $441,140 thousand, up from $318,074 thousand in 2017.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2018filed February 13, 2019Financial Statements
FY2018 against FY2017
| Line item | FY2018FY2017 | Change |
|---|---|---|
| Revenue | $2.27B$1.86B | +22.0% |
| SG&A Expenses | $443.85M$371.27M | +19.6% |
| Operating Income | $331.38M$288.28M | +15.0% |
| Interest Expense | $63.77M$29.78M | +114.2% |
| Net Income | $226.37M$123.36M | +83.5% |
| EPS (Basic) | $4.72$2.60 | +81.5% |
| EPS (Diluted) | $4.62$2.54 | +81.9% |
| Shares Outstanding (Basic) | 47.95M47.48M | +1.0% |
| Shares Outstanding (Diluted) | 49.02M48.56M | +0.9% |
05—Questions
Frequently Asked Questions
What drove the increase in Charles River's 2018 revenue?
Revenue rose $408.5 million, or 22.0%, to $2.27 billion. The filing attributes the increase primarily to growth in the DSA and Manufacturing segments and to the acquisitions of MPI Research, KWS BioTest and Brains On-Line. DSA revenue grew 34.4%, while RMS revenue grew 5.3%, driven by research model demand in China and higher research model services revenue.
How did the company finance its 2018 acquisitions?
The MPI Research acquisition, at a purchase price of $829.7 million in cash, was funded by borrowings on the $2.3B Credit Facility and the issuance of $500.0 million of 5.5% Senior Notes due 2026. Net proceeds from the notes of $493.8 million were used to partially repay the revolving credit facility. Total debt reached $1,654,988 thousand at year-end.
What is the Citoxlab acquisition and how will it be funded?
On February 13, 2019, Charles River signed a binding offer to acquire Citoxlab, a non-clinical CRO, for EUR 448 million in cash (approximately $510 million). The transaction is expected to close in the second quarter of 2019, subject to labor consultations, regulatory requirements and customary closing conditions. It is expected to be financed through the existing revolving credit facility and cash, and it will be reported in the DSA segment.
Did Charles River return capital to shareholders in 2018?
The company did not repurchase any shares under its stock repurchase program in 2018, leaving $129.1 million remaining on the authorization. It did not pay cash dividends and does not expect to pay them in the foreseeable future. In October 2018, the Board approved the cancellation of 40.2 million treasury shares totaling $1.7 billion.
What risks does the filing highlight for the business?
The filing cites reductions in pharmaceutical and biotechnology R&D budgets, reductions or delays in government funding of research (such as NIH), contamination risks in animal populations, the outsourcing trend possibly slowing, and the growing debt load of $1.7 billion. It also notes Brexit-related uncertainty for its U.K. operations and the potential impact of new technologies that could reduce demand for research models.
06—Continue